Real-time enterprise lends greater relevance to CRM

Patients who were positive for cytomegalovirus had more immune cells circulating in their blood before they started immunotherapy. This may be one reason why these patients responded better to certain immunotherapy treatments, researchers said.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Since then, six additional CAR-T cell therapies have been introduced to the market. Four of the seven are approved for B-cell lymphomas.

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Capricor officials said the company was prepared for the meeting and does not expect it to delay the FDA’s decision on the therapy.